[Prerequisites for the implementation of Ultra® packaging to replace containers for three surgical departments: Budget impact analysis].

Objectives: Budgetary impact analysis of the replacement of three surgical departments containers with a new perforation-resistant packaging: Ultra® pouches and reels.

Methods: Comparison of projections of containers costs of use to those of Ultra® packaging over six years. For containers, the costs include washing, packaging, curative maintenance (annual costs), and preventive maintenance (every five years).

[Qualification of low temperature vaporized hydrogen peroxide sterilization: Towards greater harmonization of practices?].

Objectives: Comparing performance qualification procedures for low temperature vaporized hydrogen peroxide sterilization. Assessing conformity with draft standard ISO/DIS 22441.

Methods: Qualification reports from several providers have been compared according to specific criteria: choices of cycles, loads, sterile barrier systems, probes, biological and chemical indicators; checking of packaging integrity and exposure to sterilizing agent.

[ISO 9001 certification of a sterilization unit: Transition to the 2015 version].

Objectives: The sterilization unit of Pitié-Salpêtrière-Charles Foix hospital group is ISO 9001 certified on one of its sites. The purpose of this work is to describe how the unit prepared for the transition from the 2008 version to the 2015 version of the standard, as well as the conduct of the audit.

Methods: The pharmaceutical team has received prior training from French national organization for standardization (Afnor) to understand the new requirements and how to apply them to the sterilization unit.

[Drug administration to paediatric inpatient].

Objective: Available commercial drugs in France are often unsuitable for children. The aim of this study was, for every medicinal form orally or parenterally administered, to identify and to quantify difficulties met by the nurses administering drugs to paediatric inpatients and to propose solutions to main identified problems.

Material And Method: The study was realized in 14 hospitals by direct observation.

Baxa MicroMacrocompounder for parenteral nutrition solutions in a pediatric hospital.

The constant increase of parenteral nutrition (PN) manufacturing in our pediatric hospital led us to look for an automatic filling system. The aim of this study was to evaluate the MicroMacrocompounder (MM23) for compounding pediatric PN solutions. MM23 volumetric accuracy was tested with its different inlets (S, D, V) for volumes of sterile water for injection from 0.

[Pediatric drug preparations in French hospitals. Pediatric Group of the French Clinical Pharmacy Society].

Aims: Drug formulations that are specifically intended for pediatric use have not been widely developed in France and do not adequately meet therapeutic needs, particularly as regards hospital requirements. A multicenter study was therefore carried out to evaluate the situation.

Materials And Methods: A questionnaire was sent out in June 1998 to all French university hospital pharmacies and also to those public and private hospitals known to be involved in pediatric care.

Clinical practice guidelines for the use of albumin: results of a drug use evaluation in a Paris hospital. Tenon Hospital Paris.

Clinical practice guidelines on the prescription of albumin were instituted in our hospital according to a method which combined a review of the medical literature with experts points of view. Their broadcasting was based upon a daily patient-specific decision support which was well-documented by the prescribing physician. The method for assessing the impact was a six month analysis of the discrepancies between recommendations and clinical practice.

Evaluation of a filling system for binary pediatric solutions.

The aim of this study was to assess the use of an automatic filling system (Siframix M31 and M32 system) to prepare pediatric parenteral nutrition. Volumetric accuracy was measured for each siframix system loads cells (< 5% for 5 ml with the Siframix M32 and < 5% for 9 ml with the Siframix M31) with sterile water for injection. The minimal 20 ml of flushing sterile water of the common tubulure of the Siframix M32 (p = 0.